Literature DB >> 30977087

No indication for CALR mutation analysis in Irish patients presenting with deep vein thrombosis or pulmonary embolism.

Stephen E Langabeer1.   

Abstract

Entities:  

Year:  2019        PMID： 30977087     DOI： 10.1007/s11845-019-02018-3

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN： 0021-1265            Impact factor:   1.568


× No keyword cloud information.
  5 in total

1.  Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolism.

Authors:  Jean-Christophe Ianotto; Aurélie Chauveau; Damien Luque Paz; Aurélien Delluc; Cécile Tromeur; Marie-Anne Couturier; Maelenn Gouillou; Christian Berthou; Dominique Mottier; Valérie Ugo
Journal:  Thromb Haemost       Date:  2015-08-20       Impact factor: 5.249

2.  Thrombotic risk correlates with mutational status in true essential thrombocythemia.

Authors:  Irene Bertozzi; Edoardo Peroni; Giacomo Coltro; Giulia Bogoni; Elisabetta Cosi; Claudia Santarossa; Fabrizio Fabris; Maria L Randi
Journal:  Eur J Clin Invest       Date:  2016-07-06       Impact factor: 4.686

Review 3.  Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.

Authors:  Karlyn Martin
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

4.  Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?

Authors:  Katja Zerjavic; Boris Zagradisnik; Spela Stangler Herodez; Lidija Lokar; Marjana Glaser Krasevac; Nadja Kokalj Vokac
Journal:  Acta Haematol       Date:  2010-07-09       Impact factor: 2.195

5.  JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort.

Authors:  Jean-Christophe Ianotto; Aurélie Chauveau; Dominique Mottier; Valérie Ugo; Christian Berthou; Eric Lippert; Aurélien Delluc
Journal:  Ann Hematol       Date:  2016-10-20       Impact factor: 3.673
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.